C4 Therapeutics

C4 develops small-molecule drugs that selectively destroy disease-causing proteins through degradation.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2020
Stage of Initial Investment
Series B
Initial Investment Year
2020
C4 Portco Hover Image